| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year | 
|---|---|---|---|---|---|---|
| 
 | 
   genotype assessment | Gpr84 allele assessment. PCR, sequencing. | inbred w/CC8 (58) | both | 6wks | 2013 | 
| 
 | 
   genotyping | SNP profiling, 131,000+ genomic locations, 1-19,X. | inbred (89) | 2009 | ||
| 
 | 
   genotyping | SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. | inbred (142) | m | 2014 | |
| 
 | 
   body size and weight | Body weight and length. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
| 
 | 
   complete blood count | Hematology. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
| 
 | 
   DXA | Body mass, fat mass, lean mass, bone mineral density. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
| 
 | 
   lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
| 
 | 
   metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 | 
| 
 | 
   
body weight
             with isoniazid  | 
   Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
| 
 | 
   
histopathology
             with isoniazid  | 
   Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
| 
 | 
   
lipid profile
             with isoniazid  | 
   Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
| 
 | 
   
metabolic panel
             with isoniazid  | 
   Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
| 
 | 
   
organ weights
             with isoniazid  | 
   Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 | 
| 
 | 
   
biomarker quantification
             with DB289  | 
   Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
| 
 | 
   
body weight
             with DB289  | 
   DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
| 
 | 
   
drug and metabolite quantification
             with DB289  | 
   Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
| 
 | 
   
metabolic panel
             with DB289  | 
   Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
| 
 | 
   
organ weights
             with DB289  | 
   Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
| 
 | 
   
urinalysis
             with DB289  | 
   Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 | 
| 
 | 
   MHC haplotype tissue typing | Major histocompatibility complex (MHC) H2 haplotype. | inbred (56) | both | 2000 | |
| 
 | 
   ABR test | Auditory brainstem response. | inbred (51) | both | 3-12wks and 15-72wks | 2000 | 
| 
 | 
   open field test | Distance traveled, after first 10 min and after 55 min. | other (58) | both | 7-26wks | 2019 | 
| 
 | 
   body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 | 
| 
 | 
   open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 | 
| 
 | 
   body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 | 
| 
 | 
   gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 | 
| 
 | 
   open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 | 
| 
 | 
   body weight | Body weight | inbred (32) | m | 7-9wks | 2007 | 
| 
 | 
   hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 | 
| 
 | 
   open field test | Locomotor and anxiety-related behavior. 10 min test. | inbred (32) | m | 7-9wks | 2007 | 
| 
 | 
   tail suspension test | Immobility percentage. | inbred (32) | m | 7-9wks | 2007 | 
| 
 | 
   
body weight
             with cocaine  | 
   Body weight | inbred (45) | m | 8-11wks | 2015 | 
| 
 | 
   
open field test
             with cocaine  | 
   Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 | 
| 
 | 
   
forced swim test
             with ovariectomy  | 
   Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 | 
| 
 | 
   
open field test
             with ovariectomy  | 
   Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 | 
| 
 | 
   genotyping | SNP profiling, 132,000+ genomic locations, 1-19,X | HMDP (248) | both | 2018 | |
| 
 | 
   elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 | 
| 
 | 
   light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 | 
| 
 | 
   open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 | 
| 
 | 
   
drug and metabolite quantification
             with fluoxetine  | 
   Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 | 
| 
 | 
   
open field test
             with fluoxetine  | 
   Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. | inbred (30) | m | 9-11wks | 2011 | 
| 
 | 
   
tail suspension test
             with fluoxetine  | 
   Immobility. Fluoxetine-treated vs. control. 5 min test. | inbred (30) | m | 9-11wks | 2011 | 
| 
 | 
   
biomarker quantification
             with fluoxetine  | 
   Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 | 
| 
 | 
   tympanometry | Middle ear function. | inbred (61) | both | 15-51d | 2008 |